The current situation regarding the availability and accessibility of anticancer drugs for breast cancer in the Peruvian public health systems

被引：4

作者：

Valencia-Mesias, Guillermo ^{[1
]}

Rioja-Viera, Patricia ^{[1
]}

Morante-Cruz, Zaida ^{[1
]}

Toledo-Morote, Yura ^{[2
]}

Neciosup-Delgado, Silvia ^{[1
]}

Gomez-Moreno, Henry ^{[1
]}

机构：

[1] Natl Inst Neoplast Dis, Med Oncol Dept, Lima 15036, Peru

[2] Natl Inst Neoplast Dis, Funct Insurance Unit, Lima 15036, Peru

来源：

ECANCERMEDICALSCIENCE | 2021年 / 15卷

关键词：

breast cancer; Peru; high-cost drugs; accessibility; INEN; ADJUVANT TREATMENT; TRASTUZUMAB;

D O I：

10.3332/ecancer.2021.1224

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The availability of effective, accessible, safe and high-quality anticancer drugs for the medical treatment of cancer is fundamental in ensuring optimal healthcare in the public health system in Peru. The main objective is to assess the current situation regarding anticancer drugs (termed 'high-cost') for breast cancer, as well as an analysis of the possible factors which negatively impact access to the Peruvian public health systems.There are similarities in the availability of anticancer drugs, since most treatments are covered by the Peruvian Ministry of Health. EsSalud offers an extra monoclonal antibody (pertuzumab) in the metastatic treatment stage. Meanwhile, the National Institute of Neoplastic Diseases (INEN), mainly for metastatic disease, has relied on more tested treatments over the last year. An agreement has been reached with the armed forces, which will enable patients to receive oncology care at the INEN and, thereby, benefit from the use of high-cost drugs.

引用

页数：12

共 14 条

[1]

[Anonymous], REGISTRO CANC LIMA M

[2] An economic evaluation of trastuzumab as adjuvant treatment of early HER2-positive breast cancer patients in Colombia [J].

Antonio Buendia, Jefferson ;

Vallejos, Carlos ;

Pichon-Riviere, Andres .

BIOMEDICA, 2013, 33 (03) :411-417

[3] Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab [J].

Barrios, Carlos Henrique ;

Reinert, Tomas ;

Werutsky, Gustavo .

ECANCERMEDICALSCIENCE, 2019, 13

[4] 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J].

Cardoso, F. ;

Paluch-Shimon, S. ;

Senkus, E. ;

Curigliano, G. ;

Aapro, M. S. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Bhattacharyya, G. S. ;

Biganzoli, L. ;

Boyle, F. ;

Cardoso, M-J ;

Carey, L. A. ;

Cortes, J. ;

El Saghir, N. S. ;

Elzayat, M. ;

Eniu, A. ;

Fallowfield, L. ;

Francis, P. A. ;

Gelmon, K. ;

Gligorov, J. ;

Haidinger, R. ;

Harbeck, N. ;

Hu, X. ;

Kaufman, B. ;

Kaur, R. ;

Kiely, B. E. ;

Kim, S-B ;

Lin, N. U. ;

Mertz, S. A. ;

Neciosup, S. ;

Offersen, B., V ;

Ohno, S. ;

Pagani, O. ;

Prat, A. ;

Penault-Llorca, F. ;

Rugo, H. S. ;

Sledge, G. W. ;

Thomssen, C. ;

Vorobiof, D. A. ;

Wiseman, T. ;

Xu, B. ;

Norton, L. ;

Costa, A. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2020, 31 (12) :1623-1649

[5] ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe [J].

Cherny, N. I. ;

Sullivan, R. ;

Torode, J. ;

Saar, M. ;

Eniu, A. .

ANNALS OF ONCOLOGY, 2017, 28 (11) :2633-2647

[6]

Cuba-Fuentes M, 2018, DIMENSIONES CLAVES F, V79, DOI [10.15381/anales.v79i4.15642, DOI 10.15381/ANALES.V79I4.15642]

[7]

Lazo-Gonzales O., 2016, SISTEMA SALUD PERU S

[8]

Lopez Linares R, 2019, OTRA LUCHA CANC JUST

[9]

Nota de prensa, 2019, SALUDPOL FIRMA CONVE

[10] COST-EFFECTIVENESS OF TRASTUZUMAB IN THE ADJUVANT TREATMENT OF EARLY BREAST CANCER IN SIX LATIN AMERICAN COUNTRIES [J].

Pichon-Riviere, A. ;

Augustovski, F. ;

Garay, O. U. ;

Buendia, J. ;

Rodriguez, A. ;

Vallejos, C. ;

Huayanay, L. ;

Oliveira, C. .

VALUE IN HEALTH, 2011, 14 (07) :A538-A538

← 1 2 →